MacroGenics stock price more than doubles on successful breast cancer study

MacroGenics’ stock price more than doubles on successful breast cancer study

In a conference call with analysts, the company’s CEO was tight-lipped about the median improvement in PFS, but the results nevertheless beat many investors’ expectations.

More From BioPortfolio on "MacroGenics’ stock price more than doubles on successful breast cancer study"